Evidence map›Paper›PMID 35952705›Full record

Observational studyLancet (London, England)2022

Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study.

Eloy José Tarín-Vicente, Andrea Alemany, Manuel Agud-Dios, Maria Ubals, Clara Suñer, Andrés Antón, Maider Arando, Jorge Arroyo-Andrés, Lorena Calderón-Lozano, Cristina Casañ and 28 more

Erratum issued 2 registry-linked trialsOpen access · hybridAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Lancet (London, England), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to 2 registered trials, which are not on this map. Cited by 350 papers, 15 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
350citing papers in PubMed, 15 pooled it
48.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06156566 phase4recruitingnot on this mapstarted 2024, after this paper: background citation

European Randomised Clinical Trial on mPOX Infection

TypeinterventionalSponsorMiquel EkkelenkampRan2024 to 2026Enrolled150ConditionsMonkeypoxArmsTecovirimat Oral Capsule, Placebo
NCT07534267 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Understanding MPXV Viral Clearance in Mpox Patients and Evaluating Transmission Dynamics of MPXV and Mpox Vaccine Effectiveness in West Africa : The Republic of Guinea

Typeobservational_patient_registrySponsorLondon School of Hygiene and Tropical MedicineRan2026 to 2027Enrolled992ConditionsMpox (Monkeypox), Monkeypox
3 · Its place in the literature

Who cites it

350 citing papers in PubMed, 15 syntheses or guidelines pooled it, 668 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Pooled it
  11. Pooled it
  12. Pooled it
  13. Pooled it
  14. Pooled it
  15. Pooled it
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

290 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

38 authors at 11 institutions in 3 countries.

Eloy José Tarín-VicenteDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Andrea AlemanySkin Neglected Diseases and Sexually Transmitted Infections Section, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain.
Manuel Agud-DiosDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Maria UbalsSkin Neglected Diseases and Sexually Transmitted Infections Section, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain.
Clara SuñerSkin Neglected Diseases and Sexually Transmitted Infections Section, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain.
Andrés AntónMicrobiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Maider ArandoInfectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Jorge Arroyo-AndrésDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Lorena Calderón-LozanoDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Cristina CasañMicrobiology Department, Clinical Laboratory North Metropolitan Area, University Hospital Germans Trias I Pujol, Badalona, Spain.
José Miguel CabreraInfectious Diseases Department, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain; BCN Checkpoint, Projecte dels NOMS-Hispanosida, Barcelona, Spain.
Pep CollInfectious Diseases Department, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain; BCN Checkpoint, Projecte dels NOMS-Hispanosida, Barcelona, Spain.
Vicente DescalzoInfectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
María Dolores FolgueiraMicrobiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital i+12, Madrid, Spain; Department of Medicine, School of Medicine, Complutense University of Madrid, Madrid, Spain.
Jorge N García-PérezInfectious Diseases Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Elena Gil-CruzDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Borja González-RodríguezDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Christian Gutiérrez-CollarDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Águeda Hernández-RodríguezMicrobiology Department, Clinical Laboratory North Metropolitan Area, University Hospital Germans Trias I Pujol, Badalona, Spain; Department of Genetics and Microbiology, Autonomous University of Barcelona, Barcelona, Spain.
Paula López-RoaMicrobiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital i+12, Madrid, Spain.
María de Los Ángeles MeléndezMicrobiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital i+12, Madrid, Spain.
Julia Montero-MenárguezDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Irene Muñoz-GallegoMicrobiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital i+12, Madrid, Spain.
Sara Isabel Palencia-PérezDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital i+12, Madrid, Spain; Department of Medicine, School of Medicine, Complutense University of Madrid, Madrid, Spain.
Roger ParedesInfectious Diseases Department, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain; IrsiCaixa AIDS Research Institute, Badalona, Spain.
Alfredo Pérez-RivillaMicrobiology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital i+12, Madrid, Spain; Department of Medicine, School of Medicine, Complutense University of Madrid, Madrid, Spain.
María PiñanaMicrobiology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
Nuria PratDirecció d'Atenció Primària-Metropolitana Nord, Sabadell, Catalonia, Spain.
Aída RamirezMicrobiology Department, Clinical Laboratory North Metropolitan Area, University Hospital Germans Trias I Pujol, Badalona, Spain.
Ángel RiveroInfectious Diseases Department, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain; BCN Checkpoint, Projecte dels NOMS-Hispanosida, Barcelona, Spain.
Carmen Alejandra Rubio-MuñizDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Martí VallSkin Neglected Diseases and Sexually Transmitted Infections Section, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain.
Kevin Stephen Acosta-VelásquezRadiology Department, Hospital Universitario La Paz, Madrid, Spain.
An WangDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain.
Cristina Galván-CasasSkin Neglected Diseases and Sexually Transmitted Infections Section, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain; Department of Dermatology, Hospital Universitario de Móstoles, Madrid, Spain.
Michael MarksClinical Research Department, London School of Hygiene & Tropical Medicine, London, UK; Hospital for Tropical Diseases, London, UK; Division of Infection and Immunity, University College London, London, UK.
Pablo L Ortiz-RomeroDermatology Department, Hospital Universitario 12 de Octubre, Madrid, Spain; Research Institute Hospital i+12, Madrid, Spain; Department of Medicine, School of Medicine, Complutense University of Madrid, Madrid, Spain.
Oriol MitjàSkin Neglected Diseases and Sexually Transmitted Infections Section, University Hospital Germans Trias i Pujol, Badalona, Spain; Fight Infectious Diseases Foundation, Badalona, Spain; Universitat de Vic-Universitat Central de Catalunya (UVIC-UCC), Vic, Spain; School of Medicine and Health Sciences, University of Papua New Guinea, Port Moresby, Papua New Guinea. Electronic address: oriolmitja@hotmail.com.
Hospital Universitari Germans Trias i Pujol · ESHospital Universitario 12 De Octubre · ESVall d'Hebron Hospital Universitari · ESUniversidad Complutense de Madrid · ESResearch Institute Hospital 12 de Octubre · ESConsorci d’Atenció Primària de Salut Barcelona Esquerra · ESHospital Universitario La Paz · ESIrsiCaixa · ESUniversitat Autònoma de Barcelona · ESUniversitat de Vic - Universitat Central de Catalunya · ESUniversity of London · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIn May, 2022, several European countries reported autochthonous cases of monkeypox, which rapidly spread globally. Early reports suggest atypical presentations. We aimed to investigate clinical and virological characteristics of cases of human monkeypox in Spain.

methodsThis multicentre, prospective, observational cohort study was done in three sexual health clinics in Madrid and Barcelona, Spain. We enrolled all consecutive patients with laboratory-confirmed monkeypox from May 11 to June 29, 2022. Participants were offered lesion, anal, and oropharynx swabs for PCR testing. Participant data were collected by means of interviews conducted by dermatologists or specialists in sexually transmitted infections and were recorded using a standard case report form. Outcomes assessed in all participants with a confirmed diagnosis were demographics, smallpox vaccination, HIV status, exposure to someone with monkeypox, travel, mass gathering attendance, risk factors for sexually transmitted infections, sexual behaviour, signs and symptoms on first presentation, virological results at multiple body sites, co-infection with other sexually transmitted pathogens, and clinical outcomes 14 days after the initial presentation. Clinical outcomes were followed up until July 13, 2022.

findings181 patients had a confirmed monkeypox diagnosis and were enrolled in the study. 166 (92%) identified as gay men, bisexual men, or other men who have sex with men (MSM) and 15 (8%) identified as heterosexual men or heterosexual women. Median age was 37·0 years (IQR 31·0-42·0). 32 (18%) patients reported previous smallpox vaccination, 72 (40%) were HIV-positive, eight (11%) had a CD4 cell count less than 500 cells per μL, and 31 (17%) were diagnosed with a concurrent sexually transmitted infection. Median incubation was 7·0 days (IQR 5·0-10·0). All participants presented with skin lesions; 141 (78%) participants had lesions in the anogenital region, and 78 (43%) in the oral and perioral region. 70 (39%) participants had complications requiring treatment: 45 (25%) had a proctitis, 19 (10%) had tonsillitis, 15 (8%) had penile oedema, six (3%) an abscess, and eight (4%) had an exanthem. Three (2%) patients required hospital admission. 178 (99%) of 180 swabs from skin lesions collected tested positive, as did 82 (70%) of 117 throat swabs. Viral load was higher in lesion swabs than in pharyngeal specimens (mean cycle threshold value 23 [SD 4] vs 32 [6], absolute difference 9 [95% CI 8-10]; p<0·0001). 108 (65%) of 166 MSM reported anal-receptive sex. MSM who engaged in anal-receptive sex presented with proctitis (41 [38%] of 108 vs four [7%] of 58, absolute difference 31% [95% CI 19-44]; p<0·0001) and systemic symptoms before the rash (67 [62%] vs 16 [28%], absolute difference 34% [28-62]; p<0·0001) more frequently than MSM who did not engage in anal-receptive sex. 18 (95%) of 19 participants with tonsillitis reported practising oral-receptive sex. The median time from onset of lesions to formation of a dry crust was 10 days (IQR 7-13).

interpretationIn our cohort, monkeypox caused genital, perianal, and oral lesions and complications including proctitis and tonsillitis. Because of the variability of presentations, clinicians should have a low threshold for suspicion of monkeypox. Lesion swabs showed the highest viral loads, which, combined with the history of sexual exposure and the distribution of lesions, suggests close contact is probably the dominant transmission route in the current outbreak.

fundingNone.

Indexed as

HIV InfectionsMpox, MonkeypoxProctitisSexual and Gender MinoritiesSexually Transmitted DiseasesSmallpoxTonsillitisAdultFemaleHomosexuality, MaleHumansMaleMonkeypox virusProspective StudiesSexual BehaviorSpain

Identifiers

PMID35952705
PMCPMC9533900
OpenAlexW4292083143

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.